×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Sosei ushers in new era with Nxera Pharma name change
Fierce Pharma
The Sosei Group is making a major change to its corporate business as it renames and changes up its head office location.
3 months ago
Nxera Pharma is the New Name for Sosei Group
GlobeNewswire
New name expresses the Company's vision to lead the next era of medicine - from Japan, for Japan, and by extension, to the world – and its...
2 months ago
Deal report: Boehringer-Sosei pursuing new schizophrenia target
BioCentury
Among the deal highlights of the past seven days is a collaboration between the Sosei Heptares unit of Sosei Group Corp.
2 months ago
Sosei Heptares Earns $2.5M Formosa Milestone
Contract Pharma
Triggered by FDA approval of clobetasol propionate ophthalmic suspension for post-operative inflammation and pain following ocular surgery.
2 months ago
Boehringer, Sosei Ink Potential $732M Deal for Schizophrenia Treatment
BioSpace
Boehringer Ingelheim has paid $27.3 million upfront to Sosei Heptares to develop a small molecule agonist of GPR52 to treat the positive,...
2 months ago
Sosei Heptares hits discovery milestone in GPCR deal with Genentech
Pharmaceutical Technology
Genentech is one of many companies using Sosei Heptares GPCR know-how, with AbbVie, Eli Lilly and Pfizer all on the company's books.
7 months ago
Sosei Group renamed Nxera Pharma
The Pharma Letter
The pharma company known as Sosei Group or Sosei Heptares will now go by the name Nxera Pharma.
1 month ago
Sosei Heptares hails 'transformational' acquisition
Labiotech.eu
Sosei Group Corporation is set to acquire all shares of Idorsia Pharmaceuticals Japan Ltd and Idorsia Pharmaceuticals Korea Co., Ltd.
10 months ago
Sosei to regain rights to IBD drug after GSK discontinues programme
Clinical Trials Arena
The Sosei Heptares oral IBD drug was first licensed to GSK in 2020 and is currently in Phase I clinical development.
6 months ago
Boehringer pays €25M for option to Sosei's schizophrenia drug
Fierce Biotech
Boehringer has secured an opportunity to beef up its schizophrenia portfolio courtesy of a €25 million ($27.3 million) deal with Sosei...
2 months ago